PMID- 12779183
OWN - NLM
STAT- MEDLINE
DCOM- 20030702
LR  - 20221207
IS  - 0091-2174 (Print)
IS  - 0091-2174 (Linking)
VI  - 32
IP  - 4
DP  - 2002
TI  - Fluoxetine's effects on cognitive performance in patients with traumatic brain 
      injury.
PG  - 337-44
AB  - OBJECTIVE: There are preclinical data showing that fluoxetine stimulated 
      expression of Brain Derived Neurotrophic Factor (BDNF) and its specific tyrosine 
      kinase receptor, and caused neuritic elongation and increased dendritic branching 
      density of CA3 hippocampal pyramidal cell neurons in rodents. The latter effect 
      of fluoxetine has been referred to as neuronal remodeling. In view of this 
      preclinical data, we wondered if specific cognitive measures could serve as novel 
      therapeutic targets for fluoxetine in head-injured patients. Theoretically, 
      fluoxetine-induced "neuronal remodeling" might improve cognition, independently 
      of a primary effect on mood. METHOD: In an open-label pilot investigation, 
      fluoxetine hydrochloride (Prozac; 20-60 mg/day) was administered to a 
      heterogeneous group of five head-injured patients with either no or moderate 
      depression for a period of eight months. These patients had no histories of prior 
      treatment with antidepressant medications. They were administered cognitive and 
      memory tests at baseline and after eight months of treatment on fluoxetine. 
      RESULTS: The preliminary results showed that fluoxetine improved mood, in 
      addition to improving performance on the Trail Making Test Part A, an 
      attentional-motor speed task, and the letter-number sequencing subtest of the 
      WAIS-III, a measure reflecting "working memory." CONCLUSIONS: Although fluoxetine 
      had beneficial effects on some measures of cognition, more work is needed to 
      connect these improvements with neuronal remodeling.
FAU - Horsfield, Stefanie A
AU  - Horsfield SA
AD  - Mental Health Service Line, Department of Veterans Affairs Medical Center, 
      Washington, DC 20422, USA.
FAU - Rosse, Richard B
AU  - Rosse RB
FAU - Tomasino, Vincent
AU  - Tomasino V
FAU - Schwartz, Barbara L
AU  - Schwartz BL
FAU - Mastropaolo, John
AU  - Mastropaolo J
FAU - Deutsch, Stephen I
AU  - Deutsch SI
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Int J Psychiatry Med
JT  - International journal of psychiatry in medicine
JID - 0365646
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
SB  - IM
MH  - Aged
MH  - Brain Injuries/*complications
MH  - Cognition Disorders/diagnosis/*drug therapy/*etiology
MH  - Fluoxetine/administration & dosage/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Selective Serotonin Reuptake Inhibitors/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Trail Making Test
EDAT- 2003/06/05 05:00
MHDA- 2003/07/03 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/07/03 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 10.2190/KQ48-XT0L-2H14-5UMV [doi]
PST - ppublish
SO  - Int J Psychiatry Med. 2002;32(4):337-44. doi: 10.2190/KQ48-XT0L-2H14-5UMV.